STAT

OCTOBER 17, 2022

Research at Boston University that involved testing a lab-made hybrid version of the SARS-CoV-2 virus is garnering heated headlines alleging the scientists involved could have unleashed a new pathogen. There is no evidence the work, performed under biosecurity level 3 precautions in BU’s National Emerging Infectious Diseases Laboratories, was conducted improperly or unsafely.

364

364

PharmaVoice

OCTOBER 17, 2022

Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

246

246

Pharmacy Is Right For Me

OCTOBER 21, 2022

There are so many different types of careers within the field of pharmacy—from research and drug development to pharmacy informatics! To highlight some of the more unique career settings in the industry, we’re introducing a new page on our website— Novel Pharmacy Practice Settings —where you can explore these unique career pathways. In addition to learning more about unique pathways on our new webpage, we’ll also be featuring pharmacists who work in these unique settings on our blog.

Hospitals 130

Hospitals Labelling Vaccines Drug Development 130

European Pharmaceutical Review

OCTOBER 20, 2022

In recent years there has been significant development within the cell therapy field, as chimeric antigen receptor (CAR) T-cell therapy demonstrated an ability to transform the treatment of patients with haematological malignancies. Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?

Immunity 140

Immunity Immunization Drug Development 140

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

OCTOBER 17, 2022

Before the Covid-19 pandemic emerged, influenza trackers would begin reading tea leaves around this time of the year, looking for signs of whether there would be an early start to the flu season in the northern hemisphere and which of the various flu viruses might be responsible for the most cases over the coming winter. Flu transmission has been low since the start of the pandemic , but an odd spurt of activity in April, May, and even early June of 2022 — which coincided with the onset o

350

350

PharmaVoice

OCTOBER 20, 2022

The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.

264

264

The Thyroid Pharmacist

OCTOBER 21, 2022

Many people with Hashimoto’s feel significantly better when they remove reactive foods, replenish nutrient depletions with restorative foods and supplements, and support the gut with probiotics. But what if those steps alone don’t work? You’ll have to dig a bit deeper. It took more than the implementation of the strategies above for me to resolve all my symptoms related to Hashimoto’s.

Dosage 131

Dosage Compounding 131

STAT

OCTOBER 16, 2022

In an unusual step, the European Public Prosecutor’s Office (EPPO) confirmed it has opened an investigation into the Covid-19 contracts signed by the European Union, a move that comes shortly after numerous members of the European Parliament harshly criticized a lack of transparency surrounding an agreement with Pfizer. The EPPO is an independent public prosecution office that is responsible for investigating, prosecuting, and bringing to judgment crimes such as fraud, money laundering an

Vaccines 360

Vaccines 360

PharmaVoice

OCTOBER 21, 2022

C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

279

279

European Pharmaceutical Review

OCTOBER 17, 2022

Novartis announced that The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Pluvicto ® radioligand therapy for treatment of patients with prostate cancer. Pluvicto combines a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope (in this case lutetium-177).

Chemotherapy 124

Chemotherapy Compounding 124

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Pharmaceutical Technology

OCTOBER 19, 2022

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 for each share in cash. The deal comprises an acquisition value of $12.50 for each share in cash payable at closing along with one non-tradeable contingent value right per share (CVR) of up to another $3 in cash.

119

119

STAT

OCTOBER 16, 2022

When it comes to eradicating infectious diseases, there can be no half measures: it’s an all-or-nothing proposition. For more than three decades, eradicating polio — removing it from the face of the earth — has been the sole mission of the Global Polio Eradication Initiative (GPEI). But now, after helping drive down the global number of cases by 99.9%, and with the wild poliovirus only endemic in just two countries, this incredible initiative is in danger of becoming a victi

Vaccines 327

Vaccines 327

PharmaVoice

OCTOBER 20, 2022

Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.

Drug Development 246

Drug Development 246

pharmaphorum

OCTOBER 20, 2022

And the LIVE coverage continues as we head into Day Two… This day is set to hold even more points of interest, with the demonstration ‘CX innovation: building experiences that work for customers’ (moderated by Healthware Group’s global head of digital strategy and customer engagement Yannick Valenti), as well as the masterclass ‘How to maximise learning science to affect behaviour change’ with Meducate Global’s president, Lawrence Sherman, and MD of Healthware MedComms & SWM, Francis M

119

119

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharma Times

OCTOBER 18, 2022

Therapy is based on ACD856's indicative disease modifying effects against the condition

154

154

STAT

OCTOBER 19, 2022

Since the world began confronting a global outbreak of monkeypox in the spring, the scientific community has had plenty of reasons to rue the fact that for decades this virus has been understudied. Here’s another one: Because of that oversight, doctors treating people who have been infected with monkeypox can’t answer with certainty whether some of them will face any long-term health consequences, referred to as sequelae in the field of medicine.

333

333

PharmaVoice

OCTOBER 18, 2022

Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.

Drug Development 279

Drug Development 279

Pharmaceutical Technology

OCTOBER 21, 2022

Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers. On concluding this trial, Roche will gain the right to develop and market the licenced products across various indications, contingent on approval.

111

111

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharma Times

OCTOBER 17, 2022

Demonstrators will demand hundreds of millions of pounds ‘missing’ from ME research

148

148

STAT

OCTOBER 19, 2022

Early in the Covid-19 pandemic, the leaders of wealthy countries pledged to respond with “global solidarity.” But when vaccines to prevent the disease were developed, those same leaders pushed low and middle-income countries to the back of the queue, outbidding poorer countries, as well as COVAX, a worldwide initiative developed to achieve equitable vaccine access, to secure vaccines for themselves.

Vaccines 313

Vaccines Pharmaceutical Companies Pharmaceutical Companies 313

PharmaVoice

OCTOBER 19, 2022

Is the industry ready for a biologic discovery revolution? Charlotte Deane, chief scientist of biologics AI at Exscientia, thinks so.

246

246

European Pharmaceutical Review

OCTOBER 18, 2022

Kite announced that the European Commission (EC) has approved the use of cell therapy Yescarta ® for treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), who relapse within 12 months or are refractory to, first-line chemoimmunotherapy. The approval is based on results from the Phase III ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus standard of care (SOC) in this patient population.

Chemotherapy 111

Chemotherapy 111

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

pharmaphorum

OCTOBER 17, 2022

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. Elinzanetant is already being tested in the OASIS trials for VMS associated with menopause – an indication in which Bayer is in a head-to-head race with Astellas and its fezolinetant drug candidate – and breast cancer could represent a sizeable additional patient population for the drug.

111

111

STAT

OCTOBER 18, 2022

The director of a Boston University laboratory that conducted potentially controversial research on the viruses that cause Covid-19 said his institution didn’t clear the work with the National Institutes of Health because it wasn’t funded by the federal agency. Ronald Corley said the research, which was designed to explore what makes some SARS-CoV-2 viruses more or less pathogenic, was funded with money from the university itself.

294

294

PharmaVoice

OCTOBER 18, 2022

Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.

Drug Pricing 246

Drug Pricing 246

European Pharmaceutical Review

OCTOBER 20, 2022

Apogenix , a biopharmaceutical company developing next generation immunotherapeutics, announced that asunercept showed statistically significant benefits for hospitalised COVID-19 patients in the ASUNCTIS trial. Apogenix’s lead immunotherapy candidate, asunercept is a fully human fusion protein, consisting of the CD95 receptor and an IgG1 antibody. It is being developed for the treatment of solid tumours, haematological malignancies and viral infections such as COVID-19.

Immunity 105

Immunity Immunization 105

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharmaceutical Technology

OCTOBER 18, 2022

A new study identifies a novel cerebrospinal fluid biomarker for Parkinson’s disease, expanding the scope of possible drug targets. Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in cerebrospinal fluid (CSF) between healthy individuals and Parkinson’s patients. There is potential that these structural changes could allow for a new method of differentiating different disease subtypes, thus expanding the scope

105

105

STAT

OCTOBER 17, 2022

The University of Pennsylvania’s Division of Renal-Electrolyte and Hypertension recently made a quiet update to its history web page : it removed all references to its former co-chief, Dr. Stanley Goldfarb. For several years, Goldfarb has been a vocal critic of considering social determinants of health, racism, and anything else he considers too “woke” in medical education or health care at large.

289

289

PharmaVoice

OCTOBER 19, 2022

Major recent trial flops and what they mean for companies, patients and the industry.

299

299

European Pharmaceutical Review

OCTOBER 21, 2022

The newest revision to regulatory guidance Annex 1 illustrates more stringent contamination control requirements; it is now a regulatory expectation for manufacturers to implement comprehensive and reliable contamination control strategies. Environmental monitoring (EM) programmes can help keep you compliant, measuring the state of control of production and ensuring product safety.

105

105

Pharma Times

OCTOBER 19, 2022

Therapy treats refractory chronic immune thrombocytopenia and is available across UK

Immunity 145

Immunity Immunization 145